• Immunome has submitted a New Drug Application to the FDA for varegacestat, an oral once-daily gamma secretase inhibitor for adults with desmoid tumors, backed by a global Phase 3 RINGSIDE trial that met its primary and key secondary endpoints.
• A key insight is that RINGSIDE is the largest randomized study conducted in this rare tumor type, with data selected for oral presentation at the 2026 ASCO Annual Meeting, highlighting the clinical community’s interest in varegacestat’s profile.
• We’ll examine how the NDA submission for varegacestat, supported by robust Phase 3 progression-free survival data, influences Immunome’s broader investment narrative.

Find 48 companies with promising cash flow potential yet trading below their fair value.

What Is Immunome's Investment Narrative?

To own Immunome, you really have to believe that varegacestat can anchor a credible commercial story in rare oncology while the rest of the pipeline catches up. The fresh NDA submission for desmoid tumors crystallizes a key near term catalyst that earlier analysis only treated as an expectation; it is now a live regulatory event, backed by the largest randomized dataset in this disease and strong progression free survival data. That said, the stock has already delivered a very large 1 year total return and trades at a premium to peers on book value, so some of this optimism may be reflected in the price. The main trade off remains clear: a high potential first product opportunity against persistent losses, recent dilution and the risk of an unfavorable FDA outcome or slower than hoped uptake.

However, one of Immunome’s biggest risks is still only just coming into focus for investors. Despite retreating, Immunome's shares might still be trading above their fair value and there could be some more downside. Discover how much.

Exploring Other Perspectives

Three Simply Wall St Community fair value views span roughly US$29 to about US$174 per share, underlining just how far apart expectations sit around Immunome. When you set that spread against the binary weight now resting on the varegacestat NDA, it becomes clear you are looking at a business where sentiment can swing quickly as new information on risk and execution emerges.

Explore 3 other fair value estimates on Immunome - why the stock might be worth just $29.50!

The Verdict Is Yours

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Immunome research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Immunome research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Immunome's overall financial health at a glance.

Seeking Other Investments?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• Outshine the giants: these 18 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.